Prevents Pneumocystis jirovecii pneumonia (PCP). ANDA 210510, held by ABHAI. Atovaquone.
As of Nov 21, 2026, ANDA 210510 (Atovaquone), held by ABHAI, was first approved by FDA on May 31, 2019, with 2 approved supplements and 0 published complete response letters.
Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. Limitations of Use: Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral suspension has not been studied. The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 31, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atovaquone750MG/5ML · suspension;oral | Atovaquone | Rx |
| Nov 5, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Nov 22, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 31, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters